Eledon Pharmaceuticals, Inc. (ELDN) Stock Score, Valuation & Financial Research
Eledon Pharmaceuticals, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.
Quick answer for ELDN
Eledon Pharmaceuticals, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 2.53. These figures are a research snapshot, not a buy or sell recommendation.
What Eledon Pharmaceuticals, Inc. does
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.
Company business and revenue
Research reporting period: 2025-12-31. A research update is not a new financial filing.
How the company makes money
Eledon Pharmaceuticals is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model relies on raising capital to fund research and development activities focused on the CD40L pathway to create immunosuppressive therapies for transplantation and autoimmune diseases.
Products and services
- The company is developing tegoprubart, an anti-CD40L antibody candidate intended for use in kidney allograft transplantation, xenotransplantation, islet cell transplantation, liver transplantation, and amyotrophic lateral sclerosis (ALS).
Customer types
Clinical trial participants and healthcare institutions.
Suppliers, materials and equipment
- Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials; specific supplier names are not disclosed. Source
Business strengths to evaluate
- Deep historical knowledge of anti-CD40 Ligand biology Source
Business risks and research considerations
- No products approved for commercial sale and history of recurring net losses Source
- Dependence on successful development and regulatory approval of product candidates Source
Sources: Company research source
Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.
ELDN financial snapshot
Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.
- Wall Street Score:
- Not currently available
- Stored price:
- USD 2.53
- Market capitalization:
- 195.29M (currency not supplied)
- Revenue:
- USD 0.00
- Net income:
- USD -98.56M
- Free cash flow:
- USD -62.34M
- Cash:
- USD 6.8M
- Total debt:
- USD 467K
- EPS:
- USD -0.99
What stands out
- Free cash flow is USD -62.34M, negative for the stored period.
- The balance sheet shows USD 6.8M of cash versus USD 467K of total debt, an excess of cash over debt on these two reported measures.
- The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.
Company-specific financial comparisons
The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.
- Cash exceeds debt by USD 6.34M using the stored balance-sheet values. This does not include other obligations or restricted cash.
Questions worth answering for ELDN
Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.
- How long can ELDN fund negative free cash flow using its current cash position before it may need more debt or new shares?
- How is ELDN likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- What specifically needs to improve for ELDN to reach sustainable profitability?
- What does the current fundamental change risk warning mean for the reliability or interpretation of ELDN's score?
What the numbers mean
A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.
A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-10-01.
Research-input completeness: 73% of the scoring inputs required for this public page are currently available.
How to research ELDN
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.